Galena Biopharma (GALE) +15.5% premarket after data from a clinical trial of NeuVax presented at...

|About: Galena Biopharma, Inc. (GALE)|By:, SA News Editor

Galena Biopharma (GALE) +15.5% premarket after data from a clinical trial of NeuVax presented at ASCO reveals booster inoculations are well-tolerated and appear to maintain long-term peptide-specific immunity and reduce disease recurrence rates. Cantor Fitzgerald starts coverage of GALE at Buy, saying its breast cancer treatment "would represent major advances in prevention of disease."